India Considers Easing Price-Hike Limits On Drugs
This article was originally published in PharmAsia News
Executive Summary
Indian authorities are considering an increase in the price caps on 70 scheduled drugs as drug makers plead for relief from their rising manufacturing expenses, such as the high price of ingredients from China. Also under consideration by the chemicals ministry and the drug price regulator is suspension of the annual 10 percent limit on price increases for drugs not under direct control. The plan includes revising the prices of several bulk drugs. Of the 70 scheduled drugs, 30 are imports by multinational drug makers. (Click here for more
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.